Form 4: BioCryst CCO Charles Gayer Boosts Stake with Equity Grants

BioCryst Pharmaceuticals' President and CCO, Charles Gayer, received significant equity awards, including 471,000 restricted stock units and 986,950 stock options, on December 17, 2025.

Summary

• Charles Gayer, President and Chief Commercial Officer (CCO) of BioCryst Pharmaceuticals, Inc. (BCRX), was granted 471,000 shares of common stock in the form of restricted stock units (RSUs) on December 17, 2025.
• These RSUs will vest 25% on each of the first, second, third, and fourth anniversaries of the grant date.
• Following this transaction, Gayer beneficially owns 889,827 shares of common stock.
• Gayer also received an annual employee option grant of 986,950 derivative securities (stock options) on December 17, 2025, with an exercise price of $7.13 per share.
• These stock options become exercisable at a rate of 25% on each of the first, second, third, and fourth anniversaries of the grant date, starting December 17, 2026, and expire on December 17, 2035.
• After this transaction, Gayer beneficially owns 986,950 employee stock options.
• A Power of Attorney, dated June 11, 2025, authorizes Alane P. Barnes and Sara A. Mykrantz to prepare and file SEC reports, including Forms 3, 4, and 5, on behalf of Charles Gayer.

Sentiment

Score: 7

Explanation: The grants of restricted stock units and stock options to a key executive are a positive signal for management alignment with shareholder interests and executive retention, though they do not reflect immediate operational performance or financial results.

Positives

• The significant equity grants to a key executive like the President and CCO align management's long-term interests with those of shareholders, incentivizing sustained performance.
• The vesting schedule for both RSUs and stock options promotes executive retention over a four-year period.

Negatives

• The grants do not represent an immediate cash infusion for the executive or the company, as they are equity-based compensation with future vesting conditions.
• The value of the awards is tied to the future performance of BioCryst's stock price, introducing market risk for the executive.

Risks

• The value of the granted equity awards is subject to market fluctuations of BioCryst Pharmaceuticals, Inc. common stock.
• Forfeiture risk exists for unvested RSUs and options if the executive's employment terminates before the vesting dates.
• The exercise price of the stock options ($7.13) means the options will only have intrinsic value if the stock price rises above this level.

Future Outlook

The equity grants are designed to incentivize the executive's future performance and long-term commitment to the company, with vesting schedules extending over the next four years. This structure aims to align the executive's financial interests with the sustained growth and success of BioCryst Pharmaceuticals.

Industry Context

The granting of restricted stock units and stock options is a common practice in the biotechnology and pharmaceutical industry for executive compensation. This approach is widely used to attract, retain, and motivate key talent by linking their compensation directly to the company's stock performance and long-term value creation, which is particularly relevant in a sector with long development cycles and high R&D investment.

Comparison to Industry Standards

• The structure of annual equity awards with a multi-year vesting schedule (25% annually over four years) is a standard compensation practice for executives in the biotechnology and pharmaceutical industry, comparable to packages offered by companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals for similar roles.
• The use of both restricted stock units (RSUs) and stock options is a common dual approach, providing both retention value (RSUs) and upside potential (options) tied to stock price appreciation, consistent with industry benchmarks for executive incentives.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of executive interests with long-term shareholder value through equity-based compensation.
• Employees (Executive): Receives significant equity compensation, providing a strong incentive for continued performance and retention.

Next Steps

• Vesting of 25% of the restricted stock units on each of the first, second, third, and fourth anniversaries of December 17, 2025.
• Vesting of 25% of the employee stock options on each of the first, second, third, and fourth anniversaries of December 17, 2025, becoming exercisable from December 17, 2026.

Key Dates

Recommendation

The Form 4 filing details routine equity compensation for a key executive, which aligns management incentives with shareholder value creation through vesting schedules. It does not provide new information on operational performance or strategic shifts that would warrant a change from a 'hold' position based solely on this filing.

Keywords

BioCryst Pharmaceuticals, BCRX, Charles Gayer, Form 4, SEC filing, insider transaction, stock options, restricted stock units, equity compensation, executive compensation, corporate governance